Diabetes, Vol 43, Issue 4 593-598, Copyright © 1994 by American Diabetes Association

ARTICLES

Diminished insulin secretory reserve in diabetic pancreas transplant and nondiabetic kidney transplant recipients

AU Teuscher, ER Seaquist and RP Robertson
Department of Medicine, University of Minnesota Medical School, Minneapolis.

Although both kidney and pancreas transplantation can restore renal and pancreatic endocrine functions, the accompanying immunosuppression may cause diminished glucose tolerance in some individuals. Therefore, we determined to what extent pancreas transplantation itself and the triple immunosuppressive therapy used in pancreas transplant recipients have adverse effects on insulin secretory reserve. Beta-cell secretory reserve was assessed by the method of glucose potentiation of arginine-induced insulin secretion in 25 normoglycemic pancreas recipients, 12 nondiabetic kidney recipients using the same immunosuppressive therapy, 3 psoriasis patients treated long term with cyclosporine, 5 arthritis patients treated long term with prednisone, and their respective sex-, age-, and body mass index-matched control subjects. Levels of fasting glucose, HbA1c, and glucose disappearance rates were normal in all subjects. During the glucose potentiation study, pancreas recipients had significantly less insulin secretion than control subjects (maximal acute response [ARmax] = 1,083 +/- 93% vs. 3,938 +/- 355%, P < 0.001). Insulin responses were also decreased in kidney recipients (ARmax = 2,296 +/- 290%) vs. control subjects (4,691 +/- 554%, P = 0.001) and in psoriasis patients treated with cyclosporine (ARmax = 2,153 +/- 390%) vs. control subjects (3,962 +/- 88%, P = 0.011), but not as extreme as that seen in pancreas recipients. No abnormalities were observed in arthritis patients treated with steroids. We conclude that normoglycemic pancreas and kidney transplant recipients receiving triple immunosuppressive therapy have diminished beta-cell secretory reserve. Because this defect was present in psoriasis patients treated long term with cyclosporine, but not in arthritis patients treated long term with prednisone, this adverse effect was probably caused in part by cyclosporine.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. R. Rickels, M. H. Schutta, J. F. Markmann, C. F. Barker, A. Naji, and K. L. Teff {beta}-Cell Function Following Human Islet Transplantation for Type 1 Diabetes Diabetes, January 1, 2005; 54(1): 100 - 106. [Abstract] [Full Text] [PDF]

				R. P. Robertson Consequences on {beta}-Cell Function and Reserve After Long-Term Pancreas Transplantation Diabetes, March 1, 2004; 53(3): 633 - 644. [Abstract] [Full Text] [PDF]

				E. Oetjen, D. Baun, S. Beimesche, D. Krause, I. Cierny, R. Blume, C. Dickel, S. Wehner, and W. Knepel Inhibition of Human Insulin Gene Transcription by the Immunosuppressive Drugs Cyclosporin A and Tacrolimus in Primary, Mature Islets of Transgenic Mice Mol. Pharmacol., June 1, 2003; 63(6): 1289 - 1295. [Abstract] [Full Text] [PDF]

				C. Semakula, S. Pambuccian, R. Gruessner, D. Kendall, G. Pittenger, A. Vinik, and E. R. Seaquist Hypoglycemia after Pancreas Transplantation: Association with Allograft Nesidiodysplasia and Expression of Islet Neogenesis-Associated Peptide J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3548 - 3554. [Abstract] [Full Text] [PDF]

				J. M. Thomas, J. L. Contreras, C. A. Smyth, A. Lobashevsky, S. Jenkins, W. J. Hubbard, D. E. Eckhoff, S. Stavrou, D. M. Neville Jr., and F. T. Thomas Successful Reversal of Streptozotocin-Induced Diabetes With Stable Allogeneic Islet Function in a Preclinical Model of Type 1 Diabetes Diabetes, June 1, 2001; 50(6): 1227 - 1236. [Abstract] [Full Text]

				E. Christiansen, L. L. Kjems, A. Volund, A. Tibell, C. Binder, and S. Madsbad Insulin secretion rates estimated by two mathematical methods in pancreas-kidney transplant recipients Am J Physiol Endocrinol Metab, April 1, 1998; 274(4): E716 - E725. [Abstract] [Full Text] [PDF]